|
[1]
|
Baruch, A., Mosesova, S., Davis, J.D., Budha, N., Vilimovskij, A., Kahn, R., et al. (2017) Effects of RG7652, a Monoclonal Antibody against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (from the Phase 2 EQUATOR Study). The American Journal of Cardiology, 119, 1576-1583. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Clarke, S.L., Huang, R.D.L., Hilliard, A.T., Levin, M.G., Sharma, D., Thomson, B., et al. (2024) Genetically Predicted Lipoprotein(a) Associates with Coronary Artery Plaque Severity Independent of Low-Density Lipoprotein Cholesterol. European Journal of Preventive Cardiology, 32, 116-127. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Crea, F. and Libby, P. (2017) Acute Coronary Syndromes: The Way Forward from Mechanisms to Precision Treatment. Circulation, 136, 1155-1166. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Reyes-Soffer, G., Ginsberg, H.N., Berglund, L., Duell, P.B., Heffron, S.P., Kamstrup, P.R., et al. (2022) Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, e48-e60. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Emerging Risk Factors Collaboration, Erqou, S., Kaptoge, S., Perry, P.L., Di Angelantonio, E., Thompson, A., et al. (2009) Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA, 302, 412-423.
|
|
[6]
|
De Rosa, R., Vasa-Nicotera, M., Leistner, D.M., Reis, S.M., Thome, C.E., Boeckel, J., et al. (2017) Coronary Atherosclerotic Plaque Characteristics and Cardiovascular Risk Factors: Insights from an Optical Coherence Tomography Study. Circulation Journal, 81, 1165-1173. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Fröbert, O., Stone, G.W., Larsen, A.I., Zhou, Z., Kotinkaduwa, L.N., Engstrøm, T., et al. (2025) Relationships of HSCRP to High-Risk Vulnerable Plaque after NSTEMI: Insights from the PROSPECT II Trial. JACC: Cardiovascular Interventions, 18, 1217-1228. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Berg, K. (1963) A New Serum Type System in Man—The Lp System. Acta Pathologica Microbiologica Scandinavica, 59, 369-382. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Bittner, V.A., Szarek, M., Aylward, P.E., Bhatt, D.L., Diaz, R., Edelberg, J.M., et al. (2020) Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk after Acute Coronary Syndrome. Journal of the American College of Cardiology, 75, 133-144. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Verbeek, R., Hoogeveen, R.M., Langsted, A., Stiekema, L.C.A., Verweij, S.L., Hovingh, G.K., et al. (2018) Cardiovascular Disease Risk Associated with Elevated Lipoprotein(a) Attenuates at Low Low-Density Lipoprotein Cholesterol Levels in a Primary Prevention Setting. European Heart Journal, 39, 2589-2596. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Kamstrup, P.R., et al. (2009) Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA, 301, 2331-2339. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Virmani, R., Burke, A.P., Farb, A. and Kolodgie, F.D. (2006) Pathology of the Vulnerable Plaque. Journal of the American College of Cardiology, 47, C13-C18. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Tsimikas, S. (2017) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69, 692-711. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Duarte Lau, F. and Giugliano, R.P. (2022) Lipoprotein(a) and Its Significance in Cardiovascular Disease: A Review. JAMA Cardiology, 7, 760-769. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Fernandez, D.M., Rahman, A.H., Fernandez, N.F., Chudnovskiy, A., Amir, E.D., Amadori, L., et al. (2019) Single-Cell Immune Landscape of Human Atherosclerotic Plaques. Nature Medicine, 25, 1576-1588. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Koskinas, K.C., Häner, J., Ueki, Y., Otsuka, T., Lonborg, J., Shibutani, H., et al. (2024) Association of Lipoprotein(a) with Changes in Coronary Atherosclerosis in Patients Treated with Alirocumab. Circulation: Cardiovascular Imaging, 17, e016683. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Wu, H., Luan, J., Forgetta, V., Engert, J.C., Thanassoulis, G., Mooser, V., et al. (2021) Utility of Genetically Predicted Lp(a) (Lipoprotein [a]) and ApoB Levels for Cardiovascular Risk Assessment. Circulation: Genomic and Precision Medicine, 14, e003312. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Kronenberg, F., Mora, S., Stroes, E.S.G., Ference, B.A., Arsenault, B.J., Berglund, L., et al. (2022) Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal, 43, 3925-3946. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Nicholls, S.J., Hsu, A., Wolski, K., Hu, B., Bayturan, O., Lavoie, A., et al. (2010) Intravascular Ultrasound-Derived Measures of Coronary Atherosclerotic Plaque Burden and Clinical Outcome. Journal of the American College of Cardiology, 55, 2399-2407. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Waksman, R., Di Mario, C., Torguson, R., Ali, Z.A., Singh, V., Skinner, W.H., et al. (2019) Identification of Patients and Plaques Vulnerable to Future Coronary Events with Near-Infrared Spectroscopy Intravascular Ultrasound Imaging: A Prospective, Cohort Study. The Lancet, 394, 1629-1637. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Dai, N., Chen, Z., Zhou, F., Zhou, Y., Hu, N., Duan, S., et al. (2022) Association of Lipoprotein(a) with Coronary-Computed Tomography Angiography-Assessed High-Risk Coronary Disease Attributes and Cardiovascular Outcomes. Circulation: Cardiovascular Imaging, 15, e014611. [Google Scholar] [CrossRef] [PubMed]
|